Search research articles
Contact Us
Filters
Showing results (1-10 of 45) with videos related to
Page
of 5
Sort By:
Pharmacotherapy
|
November 19, 2003
Pharmacy education: back to the basics?
William D Figg, Michael C Cox
Current Oncology Reports
|
April 26, 2005
Angiogenesis and prostate cancer: important laboratory and clinical findings
Michael C Cox, Matthew Permenter, William D Figg
Clinical Genitourinary Cancer
|
January 24, 2006
Antiangiogenesis: a possible treatment option for prostate cancer?
Ritchie L Longoria, Michael C Cox, William D Figg
Urologic Oncology
|
May 9, 2006
The use of thalidomide in androgen-independent prostate cancer
Michael C Cox, William L Dahut, William D Figg
Shock (Augusta, Ga.)
|
August 16, 2020
What's New in Shock, September 2020?
Michael C Cox, Philip A Efron, Scott C Brakenridge
Expert Opinion on Emerging Drugs
|
August 31, 2006
Emerging drugs to replace current leaders in first-line therapy for breast cancer
Michael C Cox, Tu D Dan, Sandra M Swain
Expert Review of Anticancer Therapy
|
August 23, 2005
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Michael C Cox, Charity D Scripture, William D Figg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2004
No rational theory for drug pricing
Michael C Cox, William D Figg, Paul W Thurman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Herbal remedies in the United States: potential adverse interactions with anticancer agents
Alex Sparreboom, Michael C Cox, Milin R Acharya, et al.
Urology
|
September 6, 2005
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer
Anthony V D'Amico, Ming-Hui Chen, Michael C Cox, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 45) with videos related to
Sort By:
Page
of 5
Pharmacotherapy
|
November 19, 2003
Pharmacy education: back to the basics?
William D Figg, Michael C Cox
Current Oncology Reports
|
April 26, 2005
Angiogenesis and prostate cancer: important laboratory and clinical findings
Michael C Cox, Matthew Permenter, William D Figg
Clinical Genitourinary Cancer
|
January 24, 2006
Antiangiogenesis: a possible treatment option for prostate cancer?
Ritchie L Longoria, Michael C Cox, William D Figg
Urologic Oncology
|
May 9, 2006
The use of thalidomide in androgen-independent prostate cancer
Michael C Cox, William L Dahut, William D Figg
Shock (Augusta, Ga.)
|
August 16, 2020
What's New in Shock, September 2020?
Michael C Cox, Philip A Efron, Scott C Brakenridge
Expert Opinion on Emerging Drugs
|
August 31, 2006
Emerging drugs to replace current leaders in first-line therapy for breast cancer
Michael C Cox, Tu D Dan, Sandra M Swain
Expert Review of Anticancer Therapy
|
August 23, 2005
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Michael C Cox, Charity D Scripture, William D Figg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2004
No rational theory for drug pricing
Michael C Cox, William D Figg, Paul W Thurman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Herbal remedies in the United States: potential adverse interactions with anticancer agents
Alex Sparreboom, Michael C Cox, Milin R Acharya, et al.
Urology
|
September 6, 2005
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer
Anthony V D'Amico, Ming-Hui Chen, Michael C Cox, et al.
Page
of 5